NCT03276832 2026-03-19
Imiquimod and Pembrolizumab in Treating Patients With Stage IIIB-IV Melanoma
Mayo Clinic
Phase EARLY_PHASE1 Completed
Clinical Trials
9 trialsNCT04494113 2026-03-18
Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers From the Tissue at the Time of Hysterectomy
National Cancer Institute (NCI)
Phase EARLY_PHASE1 Active not recruiting
NCT07039760 2026-03-11
Asciminib With or Without Sildenafil for Brain Tumors
Washington University School of Medicine
Phase EARLY_PHASE1 Not yet recruiting
NCT05035706 2026-03-05
Anti-Leukemia Immune Responses After Irradiation of Extramedullary Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT07144384 2026-02-13
Intratumoral Injection of Standard Universal Donor Expanded Natural Killer Cells and TGF-beta Imprinted Natural Killer Cells for the Treatment of Skin Squamous Cell Carcinoma and Basal Cell Carcinoma
Ohio State University Comprehensive Cancer Center
Phase EARLY_PHASE1 Recruiting
NCT02210117 2026-01-07
Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT02790853 2025-10-14
Multimodal Imaging for Surveillance in Patients With Oral Potentially Malignant Disorders
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT01165632 2025-09-02
Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma
Mayo Clinic
Phase EARLY_PHASE1 Completed
NCT07089940 2025-07-29
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
Phase EARLY_PHASE1 Not yet recruiting